NASDAQ:SNPX Synaptogenix 11/12/2024 Earnings Report $5.83 -0.44 (-7.02%) As of 09/19/2025 ProfileEarnings History Synaptogenix EPS ResultsActual EPS-$4.58Consensus EPS -$1.95Beat/MissMissed by -$2.63One Year Ago EPSN/ASynaptogenix Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASynaptogenix Announcement DetailsQuarterDate11/12/2024TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Synaptogenix Earnings HeadlinesSynaptogenix (NASDAQ:SNPX) Stock Price Down 4.2% - What's Next?September 17 at 2:36 AM | americanbankingnews.comTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayJuly 1, 2025 | prnewswire.comThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.September 20 at 2:00 AM | Brownstone Research (Ad)Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyJune 26, 2025 | prnewswire.comSynaptogenix begins TAO acquisition as part of crypto treasury strategyJune 26, 2025 | uk.investing.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingJune 24, 2025 | prnewswire.comSee More Synaptogenix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email. Email Address About SynaptogenixSynaptogenix (NASDAQ:SNPX) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of small‐molecule therapeutics aimed at preserving or restoring synaptic function in neurodegenerative diseases. Its research focuses on addressing the cognitive impairment associated with conditions such as Alzheimer’s disease by targeting pathways critical to neuronal communication and synaptic health. The company’s lead candidate is in early‐phase clinical studies to assess safety, tolerability and potential efficacy in improving cognitive deficits. Leveraging a proprietary drug discovery platform, Synaptogenix has built a pipeline of novel compounds designed to modulate key synaptic processes and slow disease progression. Research collaborations with academic institutions and neuroscience centers support its preclinical and clinical development efforts. Based in the United States, Synaptogenix operates laboratories and research facilities focused exclusively on neuroscience drug discovery. The management team brings together professionals with extensive experience in biotechnology and neurodegenerative disease research, guiding the company’s mission to develop innovative treatments for patients suffering from cognitive disorders.View Synaptogenix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
